Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363309 | 0.91 | PPARA (0.61) | CNR2CNR1EPHX2PPARGPPARA | |
| SCHEMBL6364312 | 0.88 | PPARG (0.58) | CNR1EPHX2PPARGPPARAHSD17B10 | |
| SCHEMBL6358041 | 0.87 | PPARA (0.53) | CNR2CNR1PPARGPPARA | |
| SCHEMBL6359751 | 0.79 | PPARA (0.52) | PPARGPPARA | |
| SCHEMBL17283413 | 0.78 | EPHX2 (0.77) | CNR1EPHX2 | |
| SCHEMBL6418437 | 0.78 | ALDH1A1 (0.45) | CNR2CNR1PPARGPPARAMEN1 | |
| SCHEMBL27419965 | 0.77 | EPHX2 (0.75) | CNR1EPHX2 | |
| SCHEMBL19043177 | 0.75 | EPHX2 (0.80) | EPHX2HSD17B10TRPV1MEN1MAPT | |
| SCHEMBL4183114 | 0.75 | EPHX2 (0.80) | EPHX2HSD17B10TRPV1MEN1MAPT | |
| SCHEMBL1456740 | 0.75 | EPHX2 (0.80) | EPHX2HSD17B10TRPV1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075377-A1 | PPAR compounds | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169192-A1 | PPAR compounds | PPARA, PPARG, PPARD | CNR2 638/4885CNR1 450/4885EPHX2 3414/4885 |
| US-20050075377-A1 | PPAR compounds | PPARA, PPARG, PPARD | CNR2 638/4885CNR1 450/4885EPHX2 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.